- Genetic Technologies (NASDAQ:GENE) announces the launch of its COVID-19 Serious Disease Risk Test ((COVID-19 Risk Test)) in the U.S. through its partnership with Infinity BiologiX.
- Shares of the company down nearly 5% premarket.
- Designed to predict disease severity using genetic and clinical information, the test provides a risk score to help individuals aged 18 years and over to understand their personal risk of contracting a serious case of COVID-19.
- Infinity BiologiX will determine sales and end consumer pricing structure for the risk test and will produce, distribute, and market it in the US.